What's Happening?
Givaudan, a fragrance and flavor specialist, has conducted an exhibition titled 'The New Desire' to explore the profound impact of GLP-1 drugs on consumer behavior and the beauty market. The exhibition highlights
a significant increase in GLP-1 drug usage, with 11% of U.S. adults using them for weight loss in 2026, up from 3% in 2024. This trend is expected to accelerate due to factors like rising obesity rates, reduced treatment costs, new molecules, and easier oral formulations. Givaudan's research indicates that GLP-1 users are shifting spending from food to categories like beauty, sports, and travel, with a 97% increase in fine fragrance spending. The exhibition also addresses emerging consumer concerns related to GLP-1 side effects, such as temporary hair loss, bad breath, dry skin, skin laxity, and facial volume loss, often referred to as 'Ozempic face.'
Why It's Important?
The insights from Givaudan's 'The New Desire' exhibition are crucial for the beauty and fragrance industries, signaling a fundamental shift in consumer needs and preferences driven by GLP-1 drug adoption. Brands must adapt their product development and marketing strategies to address the specific concerns and evolving desires of GLP-1 users. The increased demand for functional beauty products that offer visible results, sensorial textures, and enjoyable experiences, alongside the appeal of specific fragrance types like gourmand and fresh scents, presents both challenges and opportunities. Companies that can effectively innovate to meet these new demands, focusing on efficacy and pleasure, stand to gain a competitive advantage in a rapidly changing market. This trend also underscores the broader impact of pharmaceutical advancements on consumer goods sectors.
What's Next?
Givaudan plans to continue its research into the olfactory preferences of GLP-1 users, with further studies expected by the end of 2026. The company is also championing its patented MoodScentz and DreamScentz technologies, developed through neuroscience research, to address mood and sleep disruptions experienced by some GLP-1 users. The exhibition itself, which includes AI-generated concepts and consumer feedback, is being extended due to its success, indicating a strong industry interest in understanding these shifts. Brands are encouraged to move beyond simply creating new cosmetic niches for GLP-1 users and instead anticipate broader, lasting changes in the beauty market. This proactive approach will involve decoding new generations of needs and behaviors to develop relevant and effective products.
Beyond the Headlines
The rise of GLP-1 drugs and their influence on consumer behavior extends beyond the beauty market, hinting at a broader societal transformation. The shift in spending patterns, where individuals prioritize beauty, sports, and travel over food, suggests a re-evaluation of personal values and lifestyle choices. This could lead to a redefinition of wellness, where physical appearance and emotional well-being are increasingly intertwined with medical interventions. The emphasis on 'functional fragrances' that offer both pleasure and therapeutic benefits, such as improving mood or sleep, highlights a growing consumer desire for products that cater to holistic well-being. This trend may also prompt ethical discussions within the beauty industry regarding product claims and the responsible marketing of solutions for medically induced side effects, pushing for greater transparency and evidence-based efficacy.
